These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29542269)

  • 41. Calculation of brachytherapy doses does not need TG-43 factorization. For the proposition.
    Song H
    Med Phys; 2003 Jun; 30(6):997-8. PubMed ID: 12852519
    [No Abstract]   [Full Text] [Related]  

  • 42. Permanent brachytherapy: prostate seed implants as an out-patient treatment.
    Henkel TO; Kahmann F
    Arch Ital Urol Androl; 2000 Dec; 72(4):295-301. PubMed ID: 11221059
    [TBL] [Abstract][Full Text] [Related]  

  • 43. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103.
    Rivard MJ; Butler WM; Devlin PM; Hayes JK; Hearn RA; Lief EP; Meigooni AS; Merrick GS; Williamson JF
    Brachytherapy; 2007; 6(1):34-7. PubMed ID: 17284383
    [TBL] [Abstract][Full Text] [Related]  

  • 44. COMP Report: CPQR technical quality control guidelines for use of positron emission tomography/computed tomography in radiation treatment planning.
    Klein R; Oliver M; La Russa D; Agapito J; Gaede S; Bissonnette J; Rahmim A; Uribe C
    J Appl Clin Med Phys; 2022 Dec; 23(12):e13785. PubMed ID: 36208131
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Class solution for inversely planned permanent prostate implants to mimic an experienced dosimetrist.
    Lessard E; Kwa SL; Pickett B; Roach M; Pouliot J
    Med Phys; 2006 Aug; 33(8):2773-82. PubMed ID: 16964853
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adaptation of the CVT algorithm for catheter optimization in high dose rate brachytherapy.
    Poulin E; Fekete CA; Létourneau M; Fenster A; Pouliot J; Beaulieu L
    Med Phys; 2013 Nov; 40(11):111724. PubMed ID: 24320432
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantifying the effect of seed orientation in postplanning dosimetry of low-dose-rate prostate brachytherapy.
    Collins Fekete CA; Plamondon M; Martin AG; Vigneault É; Verhaegen F; Beaulieu L
    Med Phys; 2014 Oct; 41(10):101704. PubMed ID: 25281943
    [TBL] [Abstract][Full Text] [Related]  

  • 48. AAPM Task Group 128: quality assurance tests for prostate brachytherapy ultrasound systems.
    Pfeiffer D; Sutlief S; Feng W; Pierce HM; Kofler J
    Med Phys; 2008 Dec; 35(12):5471-89. PubMed ID: 19175107
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Prostate cancer brachytherapy].
    Pommier P; Guérif S; Peiffert D; Créhange G; Hannoun-Lévi JM; de Crevoisier R
    Cancer Radiother; 2016 Sep; 20 Suppl():S210-5. PubMed ID: 27523412
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Radionuclides, technologies and quality control in brachytherapy].
    Marchesi V; Gautier M; Villani N; Feuillade J; Dejean C
    Cancer Radiother; 2013 Apr; 17(2):85-8. PubMed ID: 23474213
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of TG-43 recommended 2D-anisotropy function for elongated brachytherapy sources.
    Awan SB; Meigooni AS; Mokhberiosgouei R; Hussain M
    Med Phys; 2006 Nov; 33(11):4271-9. PubMed ID: 17153405
    [TBL] [Abstract][Full Text] [Related]  

  • 52. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy.
    Yamada Y; Rogers L; Demanes DJ; Morton G; Prestidge BR; Pouliot J; Cohen GN; Zaider M; Ghilezan M; Hsu IC;
    Brachytherapy; 2012; 11(1):20-32. PubMed ID: 22265435
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prescription dose in permanent (131)Cs seed prostate implants.
    Yue N; Heron DE; Komanduri K; Huq MS
    Med Phys; 2005 Aug; 32(8):2496-502. PubMed ID: 16193779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brachytherapy dosimetry of 125I and 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code.
    Bohm TD; DeLuca PM; DeWerd LA
    Med Phys; 2003 Apr; 30(4):701-11. PubMed ID: 12722822
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monte Carlo-aided dosimetry of the Symmetra model I25.S06 125I, interstitial brachytherapy seed.
    Hedtjärn H; Carlsson GA; Williamson JF
    Med Phys; 2000 May; 27(5):1076-85. PubMed ID: 10841412
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The evaluation of a 2D diode array in "magic phantom" for use in high dose rate brachytherapy pretreatment quality assurance.
    Espinoza A; Petasecca M; Fuduli I; Howie A; Bucci J; Corde S; Jackson M; Lerch ML; Rosenfeld AB
    Med Phys; 2015 Feb; 42(2):663-673. PubMed ID: 28102606
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Brachytherapy for prostate carcinoma].
    Yorozu A
    Nihon Igaku Hoshasen Gakkai Zasshi; 2005 Apr; 65(2):87-91. PubMed ID: 15920966
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The robustness of dose distributions to displacement and migration of 125I permanent seed implants over a wide range of seed number, activity, and designs.
    Beaulieu L; Archambault L; Aubin S; Oral E; Taschereau R; Pouliot J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1298-308. PubMed ID: 15001275
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk.
    Crook JM; Potters L; Stock RG; Zelefsky MJ
    Brachytherapy; 2005; 4(3):186-94. PubMed ID: 16182218
    [TBL] [Abstract][Full Text] [Related]  

  • 60. On the development of consensus values of reference dosimetry parameters for interstitial brachytherapy sources.
    Chan GH; Nath R; Williamson JF;
    Med Phys; 2004 May; 31(5):1040-5. PubMed ID: 15191290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.